Yaz ad gets FDA-OK make-over
Bayer is airing a corrective television ad campaign for its oral contraceptive Yaz (drospirenone/ethinyl estradiol), in response to an agency warning letter it received last fall (1"The Pink Sheet," Oct. 13, 2008, p. 21). The campaign will more clearly say Yaz is indicated to treat symptoms for premenstrual dysphoric disorder, not premenstrual syndrome, and moderate, not mild, acne. The ad is markedly different from the 2008 campaign and features one woman talking about the product and indications (with no balloons), Bayer said. It will run through August
You may also be interested in...
FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month
The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.
A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries.